In Brief: Pathogenesis TOBI
Pathogenesis TOBI: Inhaled tobramycin NDA for chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients will be filed in second quarter, company says in announcing Phase III trial results for TOBI. Two trials in 468 patients found that TOBI improved lung function 11% over placebo; mean hospitalization declined 36% to 5.2 days for the TOBI group compared to 8.2 days for placebo...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth